STAAR SURGICAL (STAA)
Health Care · Ophthalmic medical devices / refractive surgery · NASDAQ
STAAR Surgical designs and manufactures implantable collamer lenses (ICLs) for refractive vision correction, offering reversible alternatives to corneal refractive surgery.
What STAAR SURGICAL does
STAAR Surgical designs, develops, manufactures, and sells implantable collamer lenses (ICLs) for refractive vision correction and related delivery systems. The company's ICLs are phakic lenses made from Collamer, a proprietary collagen copolymer material, which are implanted into the eye without removing the natural crystalline lens. STAAR markets its ICLs under the EVO family for myopia correction, including the newer EVO Viva with extended depth of focus for presbyopia treatment, as well as Visian ICL for hyperopia correction, with toric versions available to address astigmatism. Approximately 100% of revenue is generated from ICL sales globally.
Themes: refractive surgery, vision correction, ophthalmology, medical aesthetics
Fundamentals
- Price$23.14 as of 2026-08-21 close
- Market cap$1.2B as of 2026-08-21
- 1-year return-16.7% 2025-08-21 close $27.77 → 2026-08-21 close $23.14
- P/En/a negative earnings
- Net margin-7.2% as of 2026-08-24
- Gross margin+76.9% as of 2026-08-24
- ROE-6.1% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Revenue growth (YoY)+4.0% as of 2026-08-24
- Revenue CAGR (3y)+0.0% SEC XBRL
- Beta1.19 as of 2026-08-24
- Last reported earnings2026-08-12 SEC EDGAR Form 8-K (Item 2.02)
How STAA compares in its sector
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- gross marginmiddle range 384 covered Health Care peers, as of 2026-08-24
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRbottom 25% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2026
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How STAAR SURGICAL looks technically
STAAR SURGICAL (STAA) is trading 4.2% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed above its 200-day average about 61 trading days ago — a "golden cross", a bullish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 16, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 40, neither overbought (above 70) nor oversold (below 30). It made a new 20-day low about 19 trading days ago. It is 35.5% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 4.2% below its 200-day average, the long-term trend line — a long-term downtrend | -4.2% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $26.31 | $26.31 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $24.15 | $24.15 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing high 7 calendar days ago — the swings before that are what the structure reading is measured on | 7 sessions |
| Wave structure | its recent swings can be read as a completed three-part upward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes above 26.245. It is the only labelling that fits, and it describes the swings already printed, not what comes next. | possible three-wave upward correction, complete |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 61 trading days ago — a "golden cross", a bullish long-term signal | 61 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 16, below the 25 that marks a real trend) | 15.9 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 40, neither overbought (above 70) nor oversold (below 30) | 40.2 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($22.20 to $26.25) — its "stochastic" reading is 23 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 23.2 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 11 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $35.87 | $35.87 |
|---|---|---|
| From the 52-week high | it is 35.5% below its 52-week high (its highest price of the past year) | -35.5% |
| Above the 52-week low | it is 48.5% above its 52-week low (its lowest price of the past year) | +48.5% |
| Below the 52-week high | it is 35.5% below its highest point of the past year | 35.5% |
| Since a 20-day breakout | it made a new 20-day low about 19 trading days ago | 19 sessions |
| Since a 55-day breakout | it made a new 55-day low about 19 trading days ago | 19 sessions |
| All-time high | its highest closing price on record is $163.08 (set on 2021-09-07) | $163.08 |
| Given back of the 52-week move | over the past year its closes ranged ($16.10 to $33.34), and it has given back a bit over half of its rise from last year’s low — 59% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $22.13 to $22.69. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 59.2% |
| From the all-time high | it is 85.8% below its all-time high | -85.8% |
| Nearest price level | it is trading 2.6% below a resistance level at $23.73 — a price it turned at three times since 2024-12-16, most recently on 2026-04-16. Since 2024-08-21 it has 8 such levels below the current price and 11 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +2.6% |
| All-time low | its lowest closing price on record is $0.79 (set on 2009-04-07) | $0.79 |
| Above the all-time low | it is 2829.1% above its all-time low | +2,829% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are narrower than usual versus its own recent 6-month history (tighter than about 79% of it) | 21st percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $1.40 between its high and its low — about 6.0% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $1.40 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $22.27 and $26.06 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $22.27 – $24.16 – $26.06 |
| Typical daily range (% of price) | its price moves about 6.0% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 6.0% |
| Stretch from the 200-day average | it is trading 0.7 daily ranges below its 200-day average price (4.2% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 0.7 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.66× |
|---|
Analyst
2
| Change in the average price target | analysts have cut their average price target by 2.4% since the prior reading | -2.4% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating has softened toward "sell" since the prior reading | 0.03 toward sell |
Candlestick patterns
1
| Since a doji | 2 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 2 sessions ago |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-08-21 0.1% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -0.1% |
|---|---|---|
| Open gap | it gapped 7.7% below the previous close 25 sessions ago and has not traded back through the level it left behind at 28.98 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -7.7% |
| Gap filled | a 5.4% gap down opened on 2026-08-13 has been "filled" 6 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 6 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 7.0 percentage points (the stock lost 4.7% while the market gained 2.3%) | -7.0% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 32.5 percentage points (the stock lost 29.4% while the market gained 3.1%) | -32.5% |
| vs market, 6 months | over the past 6 months this stock beat the market by 19.2 percentage points (the stock gained 30.3% while the market gained 11.1%) | +19.2% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 37.2 percentage points (the stock lost 16.7% while the market gained 20.5%) | -37.1% |
Signal agreement
2
| Bullish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, MACD momentum is positive, outperforming the market over 6 months — these describe past price behaviour, not a forecast | 3 of 9 |
|---|---|---|
| Bearish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bearish state: trading below its 200-day average, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 2 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 18% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thick, spanning 9.9% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | -18.1% |
|---|
Volume-weighted price
1
| Vs this year’s average price paid | the price is sitting right on the average price paid so far this year, so the typical buyer over that stretch is roughly break-even. That average is $23.07 — a volume-weighted average of daily closes over 157 sessions, not a true tick-by-tick VWAP. | +0.3% |
|---|
Price levels it has turned at before
STAA last closed at $23.14 on 2026-08-21. Since 2024-08-21 it has turned at 8 prices below its last close and 11 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $23.73 | Resistance | 2.6% above the last close | turned there three times · 2024-12-16 to 2026-04-16 |
| $24.43 | Resistance | 5.5% above the last close | turned there twice · 2025-11-07 to 2026-01-05 |
| $21.16 | Support | 8.6% below the last close | turned there three times · 2025-01-14 to 2026-07-28 |
| $25.42 | Resistance | 9.9% above the last close | turned there three times · 2025-01-02 to 2026-08-03 |
| $20.50 | Support | 11.4% below the last close | turned there twice · 2025-03-10 to 2026-02-25 |
| $19.44 | Support | 16.0% below the last close | turned there twice · 2025-07-28 to 2026-03-16 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part upward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes above $26.25.
It is the only labelling that fits these swings, though its proportions are not the textbook ones.
This reading has stood for 1 trading day, since 2026-08-21.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Pulled back from the 12-month high · trendless / choppy (low ADX) · Analyst price target recently CUT · beating the market · Most volatile (6%+ typical daily range) | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingHold (2.67 mean, 1=Strong Buy…5=Strong Sell) — 10 analysts
- Mean price target$27.90 range $19.00 – $37.00; median $27.50
Analyst estimates, as of 2026-08-24. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for STAA
- Consensus EPS estimate$0.1675 next reporting period, as of 2026-08-24
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Dependence on a single product line (Implantable Collamer Lenses) for substantially all revenue.","Risks associated with international regulatory approvals and commercialization in new markets.","Potential for adverse events or safety concerns related to surgical implants."]
What changed in the latest 10-Q
AI-assisted comparison of STAA's 10-Q filed 2026-05-13 against the prior one filed 2025-11-05.
Management's Discussion & Analysis (MD&A)
- Added:
- Added phrase 'globally' after 'market opportunities' in newer filing (2026-05-13)
- Added comprehensive risk factors list in newer filing (2026-05-13) including: our ability to grow and generate profit; our reliance on independent distributors in international markets; a slowdown or disruption to the Chinese economy; global economic conditions; disruptions in our supply chain; fluctuations in foreign currency exchange rates; international trade disputes (including involving tariffs) and substantial dependence on demand from Asia; changes in effective tax rate or tax laws; any loss of use of our principal manufacturing facility; competition; potential losses due to product liability claims; our exposure to environmental liability; data corruption, cyber-based attacks or network security breaches and/or noncompliance with data protection and privacy regulations; acquisitions of new technologies; climate changes; the willingness of surgeons and patients to adopt a new or improved product and procedure; extensive clinical trials and resources devoted to research and development; compliance with government regulations; the discretion of regulatory agencies to approve or reject existing, new or improved products, or to require additional actions before or after approval, or to take enforcement action; laws pertaining to healthcare fraud and abuse; changes in FDA or international regulations related to product approval; product recalls or failures; and other important factors
- Reworded:
- Changed 'implantable Collamer® lenses ("ICLs")' in older filing to 'Implantable Collamer® Lenses' in newer filing (2026-05-13) - removal of lowercase 'implantable' and parenthetical acronym
- Changed 'government approval of a new or improved products' in older filing to 'government approval of new or improved products' in newer filing (2026-05-13)
- Changed 'achieving business plans for 2025 and beyond' in older filing to 'achieving business plans for 2026 and beyond' in newer filing (2026-05-13)
- Notes:
- Older filing text appears truncated at end (cuts off after 'Form 10-K in "'), as does newer filing text, preventing full comparison of concluding sections
- Newer filing (2026-05-13) contains substantially expanded risk factors section compared to older filing (2025-11-05) which only references Form 10-K
Risk Factors
The two filings could not be meaningfully compared for this section.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for STAA — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding STAA as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 9,923,711
- Reported value $185,573,387
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 3 increased, 2 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
STAA had 4,975,558 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
STAA had 9.92% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 4.28 days to cover at the same settlement.
- Reported short interest (shares) 4,975,558
- Short interest (% of shares outstanding) 9.92%
- Prior settlement (shares) 5,094,402
- Reported change -2.33%
- Days to cover (reported) 4.28
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Alcon (ALC)
- Bausch + Lomb (BLCO)
- Carl Zeiss Meditec (AFX.DE)
- Johnson & Johnson Vision (JNJ)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare STAA vs…
Frequently asked questions
What does STAAR SURGICAL (STAA) do?
STAAR Surgical designs, develops, manufactures, and sells implantable collamer lenses (ICLs) for refractive vision correction and related delivery systems. The company's ICLs are phakic lenses made from Collamer, a proprietary collagen copolymer material, which are implanted into the eye without removing the natural crystalline lens.
What sector is STAAR SURGICAL (STAA) in?
STAAR SURGICAL (STAA) is classified in the Health Care sector. Its industry is Ophthalmic medical devices / refractive surgery. It trades on NASDAQ.
Who are STAAR SURGICAL's (STAA) competitors?
Notable peers of STAAR SURGICAL (STAA) include Alcon, Bausch + Lomb, Carl Zeiss Meditec and Johnson & Johnson Vision. This peer set is informational only — not financial advice.
Is STAAR SURGICAL (STAA) overbought or oversold right now?
STAAR SURGICAL (STAA) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 40, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on STAA come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.